⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13888653 | 1.00 | — | — | |
| SCHEMBL15133015 | 0.86 | — | — | |
| SCHEMBL23325980 | 0.83 | — | — | |
| SCHEMBL769556 | 0.81 | SPHK1 (0.30) | — | |
| SCHEMBL18994199 | 0.80 | — | — | |
| SCHEMBL10076026 | 0.78 | — | — | |
| SCHEMBL2614695 | 0.77 | — | — | |
| SCHEMBL1699644 | 0.77 | — | — | |
| SCHEMBL15362747 | 0.77 | — | — | |
| SCHEMBL10076024 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209364-A1 | COMPOUNDS AND METHODS FOR MODULATING PLP1 | IONIS PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-12018261-B2 | Compounds and methods for modulating factor XII | IONIS PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240067962-A1 | COMPOUNDS AND METHODS FOR MODULATING ATXN1 | IONIS PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240026353-A1 | COMPOUNDS AND METHODS FOR MODULATING SCN2A | IONIS PHARMACEUTICALS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11873495-B2 | Compounds and methods for reducing LRRK2 expression | IONIS PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11840689-B2 | Method of treating fatty liver disease | ASTRAZENECA AB (SE) | 2023-12-12 | — | — | US | disclosed |
| US-11833168-B2 | Compounds and methods for increasing STMN2 expression | IONIS PHARMACEUTICALS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230357770-A1 | COMPOUNDS AND METHODS FOR REDUCING APOE EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230338555-A1 | CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-11786546-B2 | Compounds and methods for modulating GFAP | IONIS PHARMACEUTICALS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-8093222-B2 | Methods for treating hypercholesterolemia | ISIS PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8088904-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110294868-A1 | MODULATION OF TRANSTHYRETIN EXPRESSION | ISIS PHARMACEUTICALS, INC. | 2011-12-01 | — | — | US | disclosed |
| US-20110172296-A1 | MODULATION OF TRANSFORMING GROWTH FACTOR-BETA 1 EXPRESSION | EXCALIARD PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| US-20110160283-A1 | MODULATION OF CD40 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110152351-A1 | MODULATION OF SMRT EXPRESSION | ISIS PHARMACEUTICALS, INC. | 2011-06-23 | — | — | US | disclosed |
| US-20110123521-A1 | METHODS FOR MODULATING EXPRESSION OF RBP4 | ISIS PHARMACEUTICALS, INC (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100130595-A1 | ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF | IONIS PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20090318536-A1 | METHODS FOR TREATING HYPERCHOLESTEROLEMIA | ISS PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090092981-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | IONIS PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |